Browse HGSNAT

Summary
SymbolHGSNAT
Nameheparan-alpha-glucosaminide N-acetyltransferase
Aliases FLJ32731; HGNAT; TMEM76; transmembrane protein 76; MPS3C
Chromosomal Location8p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Lysosome membrane Multi-pass membrane protein Note=Colocalizes with the lysosomal marker LAMP2. The signal peptide is not cleaved upon translocation into the endoplasmic reticulum; the precursor is probably targeted to the lysosomes via the adapter protein complex-mediated pathway that involves tyrosine- and/or dileucine-based conserved amino acid motifs in the last C-terminus 16-amino acid domain.
Domain PF07786 Protein of unknown function (DUF1624)
Function

Lysosomal acetyltransferase that acetylates the non-reducing terminal alpha-glucosamine residue of intralysosomal heparin or heparan sulfate, converting it into a substrate for luminal alpha-N-acetyl glucosaminidase.

> Gene Ontology
 
Biological Process GO:0006022 aminoglycan metabolic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0007034 vacuolar transport
GO:0007041 lysosomal transport
GO:0030203 glycosaminoglycan metabolic process
GO:0051259 protein oligomerization
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0008080 N-acetyltransferase activity
GO:0015019 heparan-alpha-glucosaminide N-acetyltransferase activity
GO:0016407 acetyltransferase activity
GO:0016410 N-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
Cellular Component GO:0005765 lysosomal membrane
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04142 Lysosome
hsa00531 Glycosaminoglycan degradation
hsa01100 Metabolic pathways
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolHGSNAT
Nameheparan-alpha-glucosaminide N-acetyltransferase
Aliases FLJ32731; HGNAT; TMEM76; transmembrane protein 76; MPS3C
Chromosomal Location8p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HGSNAT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolHGSNAT
Nameheparan-alpha-glucosaminide N-acetyltransferase
Aliases FLJ32731; HGNAT; TMEM76; transmembrane protein 76; MPS3C
Chromosomal Location8p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HGSNAT in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.5 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolHGSNAT
Nameheparan-alpha-glucosaminide N-acetyltransferase
Aliases FLJ32731; HGNAT; TMEM76; transmembrane protein 76; MPS3C
Chromosomal Location8p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HGSNAT in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.240.289
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4480.81
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0850.948
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2810.35
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2490.898
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3250.899
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0140.974
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3380.847
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3170.873
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4210.763
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2670.524
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0750.272
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HGSNAT in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHGSNAT
Nameheparan-alpha-glucosaminide N-acetyltransferase
Aliases FLJ32731; HGNAT; TMEM76; transmembrane protein 76; MPS3C
Chromosomal Location8p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HGSNAT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHGSNAT
Nameheparan-alpha-glucosaminide N-acetyltransferase
Aliases FLJ32731; HGNAT; TMEM76; transmembrane protein 76; MPS3C
Chromosomal Location8p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HGSNAT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HGSNAT.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHGSNAT
Nameheparan-alpha-glucosaminide N-acetyltransferase
Aliases FLJ32731; HGNAT; TMEM76; transmembrane protein 76; MPS3C
Chromosomal Location8p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HGSNAT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHGSNAT
Nameheparan-alpha-glucosaminide N-acetyltransferase
Aliases FLJ32731; HGNAT; TMEM76; transmembrane protein 76; MPS3C
Chromosomal Location8p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HGSNAT expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHGSNAT
Nameheparan-alpha-glucosaminide N-acetyltransferase
Aliases FLJ32731; HGNAT; TMEM76; transmembrane protein 76; MPS3C
Chromosomal Location8p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HGSNAT and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHGSNAT
Nameheparan-alpha-glucosaminide N-acetyltransferase
Aliases FLJ32731; HGNAT; TMEM76; transmembrane protein 76; MPS3C
Chromosomal Location8p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HGSNAT collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.